VIGL - Vigil Neuroscience, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
VIGL price evolution
VIGL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $113.69 | $90.22 | $106.54 | $121.91 |
| Long term investments | ||||
| Property, plant & equipment | $16.56 | $17.03 | $17.48 | $17.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $131.27 | $108.46 | $125.08 | $140.86 |
| Current liabilities | ||||
| Accounts payable | $0.86 | $1.42 | $1.49 | $1.95 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $30.55 | $10.76 | $8.6 | $11.66 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $42.72 | $23.19 | $21.3 | $24.61 |
| Shareholders' equity | ||||
| Retained earnings | -$283.2 | -$263.94 | -$242.71 | -$222.77 |
| Other shareholder equity | $0.11 | -$0.03 | -$0.03 | -$0.01 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $121.91 | $197.81 | $97.48 | $25.3 |
| Long term investments | ||||
| Property, plant & equipment | $17.94 | $1.4 | $1.27 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $140.86 | $200.39 | $102.44 | $25.3 |
| Current liabilities | ||||
| Accounts payable | $1.95 | $1.94 | $3.98 | $1.11 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11.66 | $11.31 | $9.88 | $2 |
| Long term debt | $0.02 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $24.61 | $11.31 | $9.95 | $6.54 |
| Shareholders' equity | ||||
| Retained earnings | -$222.77 | -$140.13 | -$71.83 | -$28.55 |
| Other shareholder equity | -$0.01 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.68 | $22.48 | $21.41 | $23.86 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.41 | $1.25 | $1.48 | $1.68 |
| Net income | ||||
| Net income | -$19.26 | -$21.23 | -$19.94 | -$22.17 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $88.87 | $68.88 | $42.41 | $27.21 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $6.24 | $0.62 | -$0.83 | -$1.31 |
| Net income | ||||
| Net income | -$82.64 | -$68.31 | -$43.28 | -$28.55 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.93 | $17.51 | $16.47 | -$65.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $25.05 | $5.19 | $5.18 | $0.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.1 | -$14.68 | -$0.23 | -$134.61 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$65.14 | -$0.92 | -$0.2 | -$0.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.89 | $161.26 | $107.75 | $29.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$134.61 | $95.19 | $68.2 | $24.15 |
News
Fundamentals
| Market cap | $319.31M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 39.67M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$82.60M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.87 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.08 |
|---|---|
| ROA | -65.34% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.72 |
| Quick ratio | N/A |